Clobazam (HR 376)

A benzodiazepine derivative that is a long-acting GABA-A RECEPTOR agonist. It is used as an antiepileptic in the treatment of SEIZURES, including seizures associated with LENNOX-GASTAUT SYNDROME. It is also used as an anxiolytic, for the short-term treatment of acute ANXIETY.

Also Known As:

Networked: 455 relevant articles (77 outcomes, 93 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Isojarvi, Jouko: 10 articles (01/2018 - 12/2012)
2.	Takahashi, Yukitoshi: 8 articles (01/2020 - 06/2005)
3.	Chiron, Catherine: 8 articles (01/2018 - 11/2003)
4.	Lee, Deborah: 8 articles (06/2016 - 12/2012)
5.	Brigo, Francesco: 7 articles (01/2021 - 01/2014)
6.	Tolbert, Dwain: 7 articles (11/2019 - 04/2012)
7.	Inoue, Yushi: 6 articles (01/2020 - 07/2012)
8.	Ng, Yu-Tze: 6 articles (05/2015 - 05/2009)
9.	Anderson, Lyndsey L: 5 articles (12/2021 - 10/2016)
10.	Bourgeois, Blaise: 5 articles (10/2018 - 07/2014)

Related Diseases

1.	Seizures (Absence Seizure) 10/22/2019 - "Clobazam as an add-on treatment may reduce seizure frequency and may be most effective in focal-onset seizures. " 04/16/2008 - "Clobazam as an add-on treatment may reduce seizure frequency and may be most effective in partial onset seizures. " 02/01/2021 - "Add-on CBD was effective in reducing seizures in the overall populations and in conjunction with clobazam. " 08/01/2016 - "Higher-evening differential dose of clobazam improved seizure control in patients with predominantly nighttime and early-morning seizures. " 10/01/2015 - "Clobazam treatment was effective in reducing drop seizures regardless of aggression experience."
2.	Epilepsy (Aura) 06/01/2003 - "The efficacy of Clobazam coupled with the lack of significant side effects noted in our study makes it merit consideration as monotherapy in adult patients with epilepsy." 01/01/2020 - "Clobazam is an effective treatment for ensuring seizure freedom in pediatric epilepsy, mostly drug-resistant. " 07/01/2015 - "Clobazam: A Safe, Efficacious, and Newly Rediscovered Therapeutic for Epilepsy." 11/01/1993 - "These data suggest that clobazam is effective in the treatment of children with a wide range of epilepsies and seizure types and support the clinical impression that clobazam is associated with less neurotoxicity than the 1,4-benzodiazepines." 09/01/2014 - "Intermittent clobazam prophylaxis in hot water epilepsy is safe and effective: a prospective study."
3.	Lennox Gastaut Syndrome 05/01/2014 - "The two randomized, controlled studies that led to the US FDA approval, as well as the follow-up multicenter, open-label study of clobazam, showed ≥50% seizure reduction for more than 50% of Lennox-Gastaut syndrome patients, while none of the other FDA-approved treatments for LGS have demonstrated efficacy rates better than 50%. " 12/01/2012 - "Long-term safety and efficacy of clobazam for Lennox-Gastaut syndrome: interim results of an open-label extension study." 11/01/2012 - "Results from a dosage-ranging, double-blind, multi-centre, phase II trial add further support for the efficacy of clobazam in paediatric and adult patients with Lennox-Gastaut syndrome (n = 61 evaluable). " 04/01/2014 - "To determine long-term safety and efficacy of adjunctive clobazam for patients with Lennox-Gastaut syndrome (LGS). " 11/01/2019 - "Pharmacokinetic data were combined from 3 CLB trials (OV-1012, OV-1017, and study 301) and a simulated study (study 401) for a total of 1306 CLB and 1305 N-desmethyl clobazam (N-CLB) samples from 193 Lennox-Gastaut syndrome patients and healthy subjects aged 6 months to 45 years. "
4.	Myoclonic Epilepsies (Myoclonic Encephalopathy) 11/01/2019 - "Our study highlights the involvement of both pharmacodynamic and pharmacokinetic interactions between CBD and clobazam that may contribute to its efficacy in Dravet syndrome." 01/01/2020 - "We analyzed AEs and efficacy at M1 (month 1), M2, and M6, comparing two sets of subgroups: Dravet syndrome (DS) vs. Lennox-Gastaut (LGS) and patients with clobazam (CLB+) vs. patients without (CLB-). " 11/01/2019 - "We then used the Scn1a+/- mouse model of Dravet syndrome to examine how CBD and clobazam interact. " 11/01/2019 - "To describe the use of a population pharmacokinetic (PopPK) model incorporating weight and ontogeny to identify effective clobazam (CLB) dosing for use in a clinical trial in pediatric patients with Dravet syndrome. " 11/01/2019 - "Pharmacometrics of clobazam in pediatrics: Prediction of effective clobazam doses for Dravet syndrome."
5.	Drug Resistant Epilepsy 02/01/2012 - "Clobazam offers a new treatment option for patients with refractory epilepsy. " 11/01/1993 - "Open study of clobazam in refractory epilepsy." 01/01/1986 - "Preliminary studies of patients who had brain damage, intractable epilepsy, and mental subnormality showed that clobazam in small doses (20 to 30 mg/day) was beneficial, and indicated that a more detailed investigation was worthwhile. " 11/01/2023 - "In patients with concomitant treatment with clobazam (CLB), the median percentage of seizure reduction was higher than those not taking CLB: 94.72% (IQR: 87.25-100) vs 41.50% (p = 0.044) and also higher than the control group of patients with refractory epilepsy not related to anti-GAD65 treated with the same combination: 94.72% (IQR: 87.25-100) vs 45.00% (IQR: 25.00-87.00) (p = 0.019). " 08/01/2023 - "Clobazam can be a safe and tolerable, add-on treatment older adults with drug-resistant epilepsy. "

Related Drugs and Biologics

1.	Valproic Acid (Depakote)
2.	Anticonvulsants (Antiepileptic Drugs)
3.	Topiramate (Topamax)
4.	Lamotrigine (Lamictal)
5.	Felbamate (Felbatol)
6.	Levetiracetam (Keppra)
7.	Phenobarbital (Luminal)
8.	Clonazepam (Rivotril)
9.	Cannabidiol
10.	rufinamide

Related Therapies and Procedures

1.	Therapeutics
2.	Ketogenic Diet
3.	Induced Hyperthermia (Thermotherapy)
4.	Oral Administration
5.	Off-Label Use